Evidence mapPaperPMID 41373505Full record

ArticleInternational journal of molecular sciences2025

Transferrin-Functionalized Liposomes Enhance MAPT-ASO Transport Across a 3D Blood-Brain Barrier Microvascular Network Model.

Simon Konig, Xinai Shen, Giuseppe Mantovani, Gerlof Sebastiaan Winkler, Zheying Zhu, Emad Moeendarbary

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Simon KonigDepartment of Mechanical Engineering, University College London, London WC1E 6BT, UK.ORCID 0000-0002-1052-0304
Xinai ShenSchool of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0009-0007-2112-0510
Giuseppe MantovaniSchool of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-0837-0351
Gerlof Sebastiaan WinklerSchool of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-0476-162X
Zheying ZhuSchool of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-2135-3812
Emad MoeendarbaryDepartment of Mechanical Engineering, University College London, London WC1E 6BT, UK.ORCID 0000-0002-7019-3907

Funding

Biotechnology and Biological Sciences Research Council BB/V001418/1Cancer Research UK C57744/A22057Engineering and Physical Sciences Research Council EP/W009889/1
6 · The paper itself

Abstract

Tau pathology is a defining hallmark of Alzheimer's disease (AD), closely associated with cognitive decline. Antisense oligonucleotides targeting the tau-encoding gene

Indexed as

Blood-Brain BarrierLiposomesOligonucleotides, Antisensetau ProteinsTransferrinBiological TransportEndothelial CellsHumansMicrovesselsLiposomesMAPT protein, humanOligonucleotides, Antisensetau ProteinsTransferrinAlzheimer’s diseaseantisense oligonucleotides (ASO)blood–brain barrier modelneurotherapeuticstargeted liposomal deliverytau protein

Identifiers

PMID41373505
PMCPMC12691827

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.